Novel approaches to pulmonary fibrosis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 6, 2014, Pages s45-s49

  Jenkins, Gisli ^a   Goodwin, Amanda ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

biomarkers; Idiopathic pulmonary fibrosis; nintedanib; pirfenidone

Indexed keywords

BIOLOGICAL MARKER; INDOLE DERIVATIVE; NINTEDANIB; PIRFENIDONE; PYRIDONE DERIVATIVE;

HUMAN; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY;

BIOMARKERS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES;

EID: 84973413713     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-6-s45     Document Type: Article

References (30)

1. Navaratnam, V, Fleming, KM, West, J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66 (2011), 462–467 10.1136/thx.2010.148031.
2. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824 10.1164/rccm.2009-040GL.
3. John, AE, Luckett, JC, Tatler, AL, et al. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med 54 (2013), 2146–2152 10.2967/jnumed.113.120592.
4. Camelo, A, Dunmore, R, Sleeman, MA, Clarke, DL, The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol, 4, 2014, 173 10.3389/fphar.2013.00173.
5. Chilosi, M, Carloni, A, Rossi, A, et al. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/ emphysema. Transl Res 162 (2013), 156–173 10.1016/j.trsl.2013.06.004.
6. Goodwin, A, Jenkins, G, Role of integrin-mediated TGFβ activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 7 (2009), 849–854 10.1042/BST0370849.
7. Tatler, AL, John, AE, Jolly, L, et al. Integrin αvβ5 mediated TGF-β activation by airway smooth muscle cells in asthma. J Immunol 187 (2011), 6094–6107 10.4049/jimmunol.1003507.
8. Jenkins, RG, Su, X, Su, G, et al. Ligation of protease-activated receptor 1 enhances αvβ6 integrin-dependent TGF-β activation and promotes acute lung injury. J Clin Invest 116 (2006), 1606–1614 10.1172/JCI27183.
9. q. Am J Pathol 174 (2009), 1264–1279 10.2353/ajpath.2009.080160.
10. Henderson, NC, Arnold, TD, Katamura, Y, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19 (2013), 1617–1624 10.1038/nm.3282.
11. Wuyts, WA, Agnostini, C, Antoniou, K, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 41 (2013), 1207–1218 10.1183/09031936.00073012.
12. Fingerlin, TE, Murphy, E, Zhang, W, et al. Genome-wide association study identified multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45 (2013), 613–620 10.1038/ng.2609.
13. Vancheri, C, Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 22 (2013), 265–272 10.1183/09059180.00003613.
14. Cancer Research UK. Cancer Statistics Report: Cancer Mortality in the UK in 2011. 2013, CRUK, London.
15. Seibold, MA, Wise, AL, Speer, MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Eng J Med 364 (2011), 1503–1512 10.1056/NEJMoa1013660.
16. Peljto, AL, Zhang, Y, Fingerlin, TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309 (2013), 2232–2239 10.1001/jama.2013.5827.
17. Richards, TJ, Kaminski, N, Baribaud, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am I Respir Crit Care Med 185 (2012), 67–76 10.1164/rccm.201101-0058OC.
18. Huang, H, Peng, X, Nakajima, J, Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends 7 (2013), 172–177.
19. Maher, TM, PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 128 (2013), 148–152 10.1183/09059180.00000913.
20. Woodcock, HV, Maher, TM, The treatment of idiopathic pulmonary fibrosis. F1000 Prime Rep, 6, 2014, 16 10.12703/P6-16.
21. Demedts, M, Behr, J, Buhl, R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Eng J Med 353 (2005), 2229–2242 10.1056/NEJMoa042976.
22. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisolone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Eng J Med 366 (2012), 1968–1977 10.1056/NEJMoa1113354.
23. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Eng J Med 370 (2014), 2093–2101 10.1056/NEJMoa1401739.
24. Taniguchi, H, Ebina, M, Kondoh, Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 821–829 10.1183/09031936.00005209.
25. Noble, PW, Albera, C, Bradford, WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769 10.1016/S0140-6736(11)60405-4.
26. Spagnolo, P, Del Giovane, C, Luppi, F, et al. Non-steroid agents for idiopathic pulmonary fibrosis (review). Cochrane Database Syst Rev, Sept 8, 2010, CD.
27. King, TE, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Eng J Med 370 (2014), 2083–2092 10.1056/NEJMoa1402582.
28. Azuma, A, Taguchi, Y, Ogura, T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res, 12, 2011, 143 10.1186/1465-9921-12-143.
29. National Institute for Health and Clinical Evidence. Pirfenidone for treating idiopathic pulmonary fibrosis (NICE technology appraisal guidance), 2013, NICE Available online at http://guidance.nice.org.uk/ta282 [Accessed 2 June 2014].
30. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082 10.1056/NEJMoa1402584.